The new catheter is a gentle, all-in-one solution that has been developed for people living with bladder and urinary problems.
It features a no-touch dry sleeve as well as an omnidirectional tip, which can bend to follow the curves of the urethra.
The SpeediCath Flex Set has a soft-squeeze grip that safely guides the tip into the urethra without making contact.
It helps patients catheterise at home or away and also supports them in managing conditions and sustaining healthy lifestyles.
The company stated that all the SpeediCath catheters have Triple Action Coating Technology, which is intended to reduce the risk of urethral damage as well as urinary tract infections (UTIs).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
It also noted that the Triple Action Coating Technology in the catheter is an option for people with spinal cord injuries (SCI).
Coloplast North America Chronic Care senior vice-president Manu Varma said: “With SpeediCath Flex Set, we are introducing an important solution for people living with SCI and many other health conditions.
“We are confident that its new innovative design will make a big difference to our users, improving their catheterisation routine in many ways.”
The company is offering the SpeediCath Flex Set as a catheter and bag solution, also known as a Closed System.
It said that the new all-in-one solution is available in standard and pocket sizes.
The new SpeediCath Flex is reclosable and features non-medical, practical packaging for safe hygiene handling and disposal.
In 2020, Coloplast acquired Nine Continents Medical, an implantable tibial nerve stimulation (ITNS) treatment developer, in a deal valued at $145m.